Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of extended weekly oral ModraDoc006/r in advanced solid tumours
2017-000347-41Phase 2Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ModraDoc006 in Non-hematologic malignancy, sponsored by Modra Pharmaceuticals. Primary endpoint: Primary safety endpoint. Started Feb 2017; status: completed.
02
Drugs
ModraDoc006
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2017-000347-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000347-41.